Hip replacement patients may need less blood transfusions with right drug dose
NCT ID NCT03822793
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested three different doses of tranexamic acid, a drug that helps blood clot, to see which works best for reducing blood loss during hip replacement surgery. 170 patients were randomly assigned to receive either a placebo or one of three doses of the drug right at the start of surgery. The goal was to find the dose that minimizes hemoglobin drop and the need for blood transfusions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tranexamic acid (Exacyl)
What this could lead to
If successful, this study could identify the best dose of tranexamic acid to reduce blood loss and transfusion needs during hip replacement surgery.
What could go wrong
This is a small, single-center phase 2 trial, so results may not apply to all patients. The optimal dose found here needs confirmation in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTHROPATHY OF HIP are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Saint-Etienne
Saint-Etienne, France